United Therapeutics Corp
NASDAQ:UTHR
United Therapeutics Corp
Long-Term Debt
United Therapeutics Corp
Long-Term Debt Peer Comparison
Competitive Long-Term Debt Analysis
Latest Figures & CAGR of Competitors
Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
United Therapeutics Corp
NASDAQ:UTHR
|
Long-Term Debt
$200m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
49%
|
|
Abbvie Inc
NYSE:ABBV
|
Long-Term Debt
$63.8B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
13%
|
CAGR 10-Years
16%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Long-Term Debt
$21.5B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
10%
|
|
Amgen Inc
NASDAQ:AMGN
|
Long-Term Debt
$60.1B
|
CAGR 3-Years
24%
|
CAGR 5-Years
15%
|
CAGR 10-Years
7%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Long-Term Debt
$361.5m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-4%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Long-Term Debt
$2.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
31%
|
CAGR 10-Years
18%
|
See Also
What is United Therapeutics Corp's Long-Term Debt?
Long-Term Debt
200m
USD
Based on the financial report for Mar 31, 2024, United Therapeutics Corp's Long-Term Debt amounts to 200m USD.
What is United Therapeutics Corp's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
49%
Over the last year, the Long-Term Debt growth was -75%. The average annual Long-Term Debt growth rates for United Therapeutics Corp have been -37% over the past three years , -28% over the past five years , and 49% over the past ten years .